🟢 Kura Oncology is trading 5% up in pre-market

Kura Oncology is trading at $11.20, up +5.16%, in pre-market; no clearly confirmed October 5 catalyst directly explaining the move was found.

• UBS reiterated a Buy rating and $15 price target, citing early KOMZIFTI launch progress; the report does not establish that this caused the gain.
• Broader indices were modestly lower, so available market context does not explain the rise.